the company’s novel dual receptor inhibitor of prostaglandin (PGE2) signaling, in a Phase 2 clinical trial for the treatment of patients with Familial Adenomatous Polyposis (FAP). “Receiving the FDA’s ...

a novel dual receptor inhibitor of prostaglandin or PGE2 signaling, for the treatment of Familial Adenomatous Polyposis or FAP. The clearance follows the successful submission of the IND ...

Technological advancements over the past few decades have unraveled the diversity and adaptability of tumors, shedding light ...

the company’s novel dual receptor inhibitor of prostaglandin (PGE2) signaling, in a Phase 2 clinical trial for the treatment of patients with Familial Adenomatous Polyposis (FAP). “Receiving ...